The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at higher risks of severe infection from the illness. In addition, staff illness and restructuring of services to deal with the crisis will inevitably place treatment capacities under significant strain. These guidelines aim to expand on those provided by NHS England regarding cancer care during the coronavirus pandemic by examining the known literature and provide guidance in managing patients with urothelial and rarer urinary tract cancers. In particular, they address the estimated risk and benefits of standard treatments and consider the alternatives in the current situation. As a result, it is recommended that this guidance will help form a framework for shared decision making with patients. Moreover, they do not advise a one-size-fits-all approach but recommend continual assessment of the situation with discussion within and between centres.
Clinical oncology (Royal College of Radiologists (Great Britain)). 2020 Apr 24 [Epub]
K Patel, A Choudhury, P Hoskin, M Varughese, N James, R Huddart, A Birtle
The Rosemere Cancer Centre, Preston, Lancashire Teaching Hospitals, NHS Foundation, UK; The Christie NHS Foundation Trust, Manchester, UK., Division of Cancer Sciences, University of Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK., Mount Vernon Cancer Centre, Northwood, UK; Division of Cancer Sciences, University of Manchester, UK., The Beacon Centre, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, UK., Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK., The Rosemere Cancer Centre, Preston, Lancashire Teaching Hospitals, NHS Foundation, UK; Division of Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK. Electronic address: .